Keros Therapeutics Net Income 2011-2026 | KROS

Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.

Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.^[1]

It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.

The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.

Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.

It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.

However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.

Annual Net Income Keros Therapeutics

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
87 M	-187 M	-153 M	-105 M	-58.7 M	-45.4 M	-12.3 M	-1.34 M	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
87 M	-187 M	-59.5 M

Quarterly Net Income Keros Therapeutics

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-7.28 M	-30.7 M	148 M	-	-53 M	-45.3 M	-43.1 M	-	-39.4 M	-37.5 M	-35.8 M	-	-23.5 M	-27.3 M	-24.2 M	-	-20.3 M	-15.6 M	-15.9 M	-	-12 M	-10.8 M	-11.9 M	-	-3.55 M	-2.85 M	-3.18 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
148 M	-53 M	-15 M

References

Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.

Net Income of other stocks in the Biotechnology industry

Issuer	Net Income	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	-514 M	-	2.43 %	$ 254 M	Germany
Grifols, S.A. GRFS	265 M	$ 7.71	1.65 %	$ 6.83 B	Spain
Altimmune ALT	-88.1 M	$ 3.5	4.64 %	$ 308 M	USA
I-Mab IMAB	-1.47 B	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	603 M	-	-	$ 40.3 B	USA
Genfit SA GNFT	67.3 M	-	2.54 %	$ 160 B	France
Ascendis Pharma A/S ASND	-384 M	$ 221.52	-0.16 %	$ 5 B	Danmark
Biophytis SA BPTS	-31.2 M	-	-13.47 %	$ 169 M	France
Heron Therapeutics HRTX	-20.2 M	$ 0.8	2.5 %	$ 133 M	USA
Midatech Pharma plc MTP	-5.46 M	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	-8.09 M	-	-1.52 %	$ 24.7 M	USA
Applied Genetic Technologies Corporation AGTC	-18.4 M	-	-	$ 26.5 M	USA
ARCA biopharma ABIO	-83.7 M	-	1052.0 %	$ 415 M	USA
Aeterna Zentaris AEZS	-8.37 M	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	-14.8 M	-	-10.17 %	$ 12.2 K	USA
Acorda Therapeutics ACOR	-253 M	-	-24.86 %	$ 820 K	USA
Albireo Pharma ALBO	-34 M	-	-0.23 %	$ 916 M	USA
Aileron Therapeutics ALRN	-62.9 M	-	10.36 %	$ 9.8 M	USA
Acasti Pharma ACST	-9.57 M	-	4.01 %	$ 150 M	Canada
Институт стволовых клеток человека ISKJ	72.9 M	-	-	-	Russia
Avenue Therapeutics ATXI	-11.7 M	-	-52.27 %	$ 4.45 M	USA
Adverum Biotechnologies ADVM	-131 M	-	-	$ 86.2 M	USA
Acer Therapeutics ACER	-26.2 M	-	2.71 %	$ 14 M	USA
Advaxis ADXS	-48.1 M	-	-9.65 %	$ 45.9 M	USA
Ayala Pharmaceuticals AYLA	-38 M	-	-	$ 7.46 M	Israel
Immunovant IMVT	-414 M	$ 24.27	5.61 %	$ 3.68 B	USA
Incyte Corporation INCY	1.29 B	$ 90.82	0.04 %	$ 17.7 B	USA
Atreca BCEL	-97.2 M	-	-11.76 %	$ 5.79 M	USA
BioDelivery Sciences International BDSI	84.9 M	-	-4.8 %	$ 255 M	USA
BeiGene, Ltd. BGNE	287 M	-	0.49 %	$ 251 B	Cayman-islands
InMed Pharmaceuticals INM	-7.95 M	$ 0.79	-3.52 %	$ 1.93 M	Canada
INmune Bio INMB	-30 M	$ 1.23	5.13 %	$ 22.1 M	USA
Inovio Pharmaceuticals INO	-135 M	$ 1.57	-0.95 %	$ 34.8 M	USA
Innate Pharma S.A. IPHA	-52.8 M	$ 1.34	14.26 %	$ 235 M	France
Calithera Biosciences CALA	-115 M	-	-10.95 %	$ 876 K	USA
Cara Therapeutics CARA	-119 M	-	-3.03 %	$ 260 M	USA
ChemoCentryx CCXI	-132 M	-	-	$ 3.74 B	USA
Bellerophon Therapeutics BLPH	-19.8 M	-	-74.18 %	$ 955 K	USA
Checkpoint Therapeutics CKPT	-56.2 M	-	-	$ 169 M	USA
Clovis Oncology CLVS	-265 M	-	-7.23 %	$ 13 M	USA
Inventiva S.A. IVA	-49.6 M	$ 6.09	5.36 %	$ 138 M	France
Aeglea BioTherapeutics AGLE	-155 M	-	-	$ 1.01 B	USA
CureVac N.V. CVAC	-412 M	-	-	$ 867 M	Germany
Compugen Ltd. CGEN	35.3 M	$ 2.13	1.91 %	$ 199 M	Israel
KalVista Pharmaceuticals KALV	-183 M	$ 16.93	-0.41 %	$ 841 M	Britain
Akero Therapeutics AKRO	-252 M	-	-	$ 3.67 B	USA
CorMedix CRMD	163 M	$ 6.35	1.6 %	$ 457 K	USA
Arbutus Biopharma Corporation ABUS	-72.8 M	$ 4.33	2.12 %	$ 719 M	Canada
Kamada Ltd. KMDA	-2.23 M	$ 8.33	0.97 %	$ 260 M	Israel
Akouos AKUS	-86.7 M	-	0.23 %	$ 488 M	USA